about
Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imagingAccounting for pharmacokinetic differences in dual-tracer receptor density imaging.Direct characterization of arterial input functions by fluorescence imaging of exposed carotid artery to facilitate kinetic analysis.In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkersPixel-based absorption correction for dual-tracer fluorescence imaging of receptor binding potential.Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imagingQuantification of the binding potential of cell-surface receptors in fresh excised specimens via dual-probe modeling of SERS nanoparticlesImplicit and explicit prior information in near-infrared spectral imaging: accuracy, quantification and diagnostic value.In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probeIn vivo quantification of tumor receptor binding potential with dual-reporter molecular imagingHigh vascular delivery of EGF, but low receptor binding rate is observed in AsPC-1 tumors as compared to normal pancreas.In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.Vision 20/20: Molecular-guided surgical oncology based upon tumor metabolism or immunologic phenotype: Technological pathways for point of care imaging and intervention.Surgical Guidance via Multiplexed Molecular Imaging of Fresh Tissues Labeled with SERS-Coded Nanoparticles.Image-derived arterial input function for quantitative fluorescence imaging of receptor-drug binding in vivo.Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors.Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging.Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging.Quantifying receptor density in vivo using a dual-probe approach with fluorescence molecular imagingDual-tracer background subtraction approach for fluorescent molecular tomography.Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors.
P2860
Q27023605-ED3F12A5-1390-450F-8ADB-F82FCF5AC7D6Q33688285-210F19FD-36D2-4B43-B10D-8C2C323CB81FQ33901313-262280AC-3955-4E1E-BA87-F4051D9013C3Q34182033-4BC96BCB-146B-4EA9-837F-F9779F06109DQ34387497-7FCCCABB-7934-4923-8088-8987BFEBB730Q34473944-3F906FBD-7F35-4978-9F1B-92EF4D72759BQ35123624-332C29D6-86CC-419D-971A-039BB75DBCD2Q35687940-D9354655-BDAB-4245-BD4C-003AB4BD98F7Q35923805-B3908261-892A-4C9E-AE16-6AC3C67BAD35Q36479293-0228F542-DD1D-4F33-BB32-4DFBFFBB96B8Q36485041-1BB24B82-0848-4D68-B8A4-C9FB43415A49Q36647014-73C69633-61AC-419F-A340-544008596973Q36994181-E507D6A6-9B97-4730-B2B5-954988F3557EQ37161337-3D4510AD-686E-4B49-AE4A-4D20EE2C3205Q37647162-F0D1870B-FDD4-46BA-970E-863E9EE6E660Q39269129-1A81CF27-F250-49E2-8B1C-350715A2ED87Q39324948-CF159B97-1ECE-4D2B-81B2-3D89C37508FBQ39444594-2128CE56-CDDE-40BA-9EA3-F16C87473383Q41878571-B2782701-A2DE-4B7B-9476-6EAB6ECFD314Q42068966-CF4E9CD5-F1E4-4272-A1B4-01028F917F4BQ52721458-F7C12761-48A5-432A-849D-74B6B6F0BC7F
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Imaging targeted-agent binding in vivo with two probes
@en
Imaging targeted-agent binding in vivo with two probes
@nl
type
label
Imaging targeted-agent binding in vivo with two probes
@en
Imaging targeted-agent binding in vivo with two probes
@nl
prefLabel
Imaging targeted-agent binding in vivo with two probes
@en
Imaging targeted-agent binding in vivo with two probes
@nl
P2093
P2860
P356
P1476
Imaging targeted-agent binding in vivo with two probes
@en
P2093
Julia A O'Hara
Kimberley S Samkoe
Michael Jermyn
Shannon Hextrum
Subhadra Srinivasan
Tayyaba Hasan
P2860
P304
P356
10.1117/1.3449109
P577
2010-05-01T00:00:00Z